LBT-3627
From Wikipedia, the free encyclopedia
LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) intended to modulate the behavior of immune cells in cases of neurodegenerative disease such that they protect dopamine-producing cells rather than attack them. [1] The drug is currently being studied for its potential use in the treatment of Parkinson's disease.[2]